These are top 10 stocks traded on the Robinhood UK platform in July
Investing.com - RBC Capital raised its price target on CorMedix (NASDAQ:CRMD) to $17.00 from $13.00 on Friday, while maintaining an Outperform rating on the healthcare company. According to InvestingPro data, analyst targets for CRMD range from $15 to $20, with the stock delivering an impressive 206% return over the past year.
The research firm cited expected continued strength in the outpatient segment during the second half of 2025 as a key factor in its more bullish outlook for the DefenCath franchise.
RBC Capital anticipates strong performance in the coming months driven by growth in the existing MDO ordering base, LDO uptake, and acceleration in the inpatient sector.
The firm believes volume growth will significantly offset potential revenue erosion in the post-TDAPA period, with the total parenteral nutrition (TPN) opportunity potentially adding up to $150 million in peak revenues.
Additional upside could come from CMS negotiations, Medicare Advantage pricing, and expansion into other indications such as oncology, according to RBC Capital, which views CorMedix as a profitable biotech with growth momentum and no tariff or IP risks.
In other recent news, CorMedix Inc . reported a significant earnings beat for the first quarter of 2025. The company’s earnings per share (EPS) reached $0.32, doubling the forecast of $0.16, while revenue was reported at $39.1 million, surpassing expectations by over $6 million. This strong financial performance is attributed to successful product launches and strategic partnerships, notably involving the DefendCath product. The company achieved a net income of $20.6 million, marking a turnaround from a net loss in the same quarter last year. CorMedix’s cash and cash equivalents stood at $77.5 million as of March 31, 2025. In terms of future guidance, CorMedix revised its first half of 2025 net revenue guidance to approximately $70 million, indicating anticipated growth. Additionally, the company remains optimistic about a mid-year implementation start with a large dialysis operator and is targeting FDA approval for a new indication by late 2027. While the company faces potential risks such as increased R&D expenses and dependence on specific revenue sources, it continues to focus on expanding its market presence and enhancing reimbursement strategies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.